Development of a Risk Predictive Model for Erectile Dysfunction at 12 Months after COVID-19 Recovery: A Prospective Observational Study - Beyond the Abstract ...

Is Primary Retroperitoneal Lymph Node Dissection the Way Forward for Patients with Testicular Seminoma and Limited Retroperitoneal Metastases? - Beyond the Abstract ...

Therapeutic Advances in Metastatic Prostate Cancer: A Journey from Standard of Care to New Emerging Treatment. December 12, 2025 Predicting Toxicities and Survival Outcomes in De Novo Metastatic ...

Varicocele and Sperm DNA Fragmentation: New Evidence with Implications for Clinical Practice - Beyond the Abstract ...

Robotic versus Open Cystectomy with Ileal Conduit for the Management of Neurogenic Bladder: A Comparative Study - Beyond the Abstract ...

Transdermal Application of H100 Gel to the Penile Shaft in Patients with Peyronie's Disease Infiltrates the Tunica Albuginea - Beyond the Abstract ...

(UroToday.com) The 2025 SUO annual meeting featured the Huggins Medal Lecture and presentation by this year’s recipient, Dr. Peter Carroll, discussing “What I did and What I am Doing”. Important ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

Read the Full Video Transcript Diane Newman: Welcome to UroToday's Bladder Health Center of Excellence. I am Diane Newman, the center's Editor, and Adjunct Professor of Urology and Surgery at the ...

Amy Pearlman discusses penile rehabilitation strategies following prostate cancer treatment. Dr. Pearlman shares her expertise on vacuum pump therapy as a crucial component of penile rehabilitation.

Oliver Sartor hosts Michael Schweizer to discuss mevrometostat. Dr. Schweizer explains this EZH2 inhibitor targets lineage plasticity and regulates androgen receptor activity, potentially overcoming ...

Andrew Hahn discusses the LenCabo study, a randomized phase 2 trial comparing lenvatinib plus everolimus versus cabozantinib for metastatic clear cell renal cell carcinoma progressing on PD-1 ...